Imatinib Completed Phase 3 Trials for Nephrogenic Systemic Fibrosis Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00981942Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec